SCHEMBL25529652

SCHEMBL25529652

CCOc1ccc([N+](=O)[O-])c(OCC)c1Cl

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.49
ALDH1A1 P00352 5/20 0.49
MAPT P10636 6/20 0.46
RAB9A P51151 3/20 0.46
HTT P42858 1/20 0.46
TDP1 Q9NUW8 1/20 0.44
KMT2A Q03164 3/20 0.44
NPSR1 Q6W5P4 1/20 0.44
GAA P10253 1/20 0.43
MEN1 O00255 2/20 0.43
RECQL P46063 2/20 0.43
MAPK1 P28482 1/20 0.43
S1PR4 O95977 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 2/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28092289 0.84 MAPT (0.45) LMNAALDH1A1MAPTRAB9AHTT
SCHEMBL25222043 0.83 MAPT (0.44) LMNAALDH1A1MAPTRAB9AHTT
SCHEMBL5369320 0.79 ALDH1A1 (0.57) LMNAALDH1A1MAPTRAB9AHTT
SCHEMBL34473554 0.77 ALDH1A1 (0.42) LMNAALDH1A1MAPTRAB9AHTT
SCHEMBL16174936 0.77 MAPT (0.49) LMNAALDH1A1MAPTRAB9AHTT
SCHEMBL14601545 0.77 ALDH1A1 (0.63) LMNAALDH1A1MAPTRAB9AHTT
SCHEMBL6904936 0.76 GAA (0.48) LMNAALDH1A1MAPTRAB9AKMT2A
SCHEMBL11052582 0.75 ALDH1A1 (0.57) LMNAALDH1A1MAPTRAB9AHTT
SCHEMBL316689 0.75 MAPT (0.57) LMNAALDH1A1MAPTTDP1KMT2A
SCHEMBL26162631 0.75 ALDH1A1 (0.50) LMNAALDH1A1MAPTRAB9ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637435-B2 Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof FUJIFILM CORPORATION (JP) 2026-05-26 US disclosed
US-12421217-B2 Pyrazine derivative or salt thereof, and use of same FUJIFILM CORPORATION (JP) 2025-09-23 US disclosed
EP-4190402-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF FUJIFILM CORP (JP) 2025-08-27 EP disclosed
EP-4052760-B1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME FUJIFILM CORP (JP) 2024-03-13 EP disclosed
EP-4190402-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF FUJIFILM Corporation (JP) 2023-06-07 EP disclosed
EP-4190402-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF FUJIFILM Corporation (JP) 2023-06-07 EP disclosed
US-20230167074-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF FUJIFILM CORPORATION (JP) 2023-06-01 US disclosed
US-20230167074-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF FUJIFILM CORPORATION (JP) 2023-06-01 US disclosed
US-20230167074-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF FUJIFILM CORPORATION (JP) 2023-06-01 US disclosed
CN-116056766-A Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof 富士胶片株式会社 2023-05-02 CN disclosed
EP-4052760-A1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME FUJIFILM Corporation (JP) 2022-09-07 EP disclosed
US-20220259185-A1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME FUJIFILM CORPORATION (JP) 2022-08-18 US disclosed
WO-2022025174-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF 富士フイルム株式会社 2022-02-03 WO disclosed
WO-2021085582-A1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME 富士フイルム株式会社 2021-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167074-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF DHRS9, DHODH, CBR1 LMNA 4322/4885ALDH1A1 512/4885MAPT 4800/4885
US-12421217-B2 Pyrazine derivative or salt thereof, and use of same DHODH, IDH1, IDH2 LMNA 3756/4885ALDH1A1 117/4885MAPT 4437/4885
US-12637435-B2 Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof CBR1, DHODH, CBR3 LMNA 3287/4885ALDH1A1 272/4885MAPT 4812/4885
US-20220259185-A1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME DHODH, IDH1, IDH2 LMNA 3756/4885ALDH1A1 117/4885MAPT 4437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.